» Articles » PMID: 25516099

Evaluation of (99m)Tc-HYNIC-TMTP1 As a Tumor-homing Imaging Agent Targeting Metastasis with SPECT

Overview
Journal Nucl Med Biol
Publisher Elsevier
Date 2014 Dec 18
PMID 25516099
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: TMTP1 (NVVRQ) is a novel tumor-homing peptide, which specifically targets tumor metastases, even at the early stage of occult metastasis foci. Fusing TMTP1 to therapeutic peptides or proteins can increase its anti-cancer efficacy both in vivo and in vitro. Here, we labeled TMTP1 with (99m)Tc to evaluate its targeting properties in an ovarian cancer xenograft tumor mouse model and a gastric cancer xenograft mouse model.

Methods: The invasion ability of SKOV3 and highly metastatic SKOV3.ip cell lines were performed by the Transwell Invasion Assays, and then Rhodamine-TMTP1 was used to detect its affinity to these two cells. Using the co-ligand ethylenediamine-N, N'-diacetic acid (EDDA) and the bifunctional chelator 6-hydrazinonicotinic acid (HYNIC), the TMTP1 peptide was labeled with (99m)Tc. A cell-binding assay was performed by incubating cancer cells with (99m)Tc-HYNIC-TMTP1 with or without an excess dose of cold HYNIC-TMTP1. To evaluate the probe in vivo, nude mice bearing SKOV3, SKOV3.ip and MNK-45 tumor cells were established and subjected to SPECT imaging after injection with (99m)Tc-HYNIC-TMTP1. Ex vivo γ-counting of dissected tissues from the mice was used to evaluate its biodistribution.

Results: (99m)Tc-HYNIC-TMTP1 was successfully synthesized. The radiotracer also exhibited high hydrophilicity and excellent stability in vitro and in vivo. It has strong affinity to highly metastatic cancer cell lines but not to poorly metastatic cell lines. After mice were injected with (99m)Tc-HYNIC-TMTP1, non-invasive SPECT imaging detected SKOV3.ip and MNK-45 xenograft tumors but not SKOV3 xenograft tumors. This result can be inhibited by excess HYNIC-TMTP1. The uptake of (99m)Tc-HYNIC-TMTP1 in SKOV3.ip xenograft tumors was 0.182±0.017% ID/g at 2h p.i. with high renal uptake (74.32±15.05% ID/g at 2h p.i.).

Conclusion: (99m)Tc-HYNIC-TMTP1 biodistribution and SPECT imaging demonstrated its ability to target highly metastatic tumors. Therefore, metastasis can be non-invasively investigated by SPECT imaging using (99m)Tc-HYNIC-TMTP1. Meanwhile, this radiotracer has some shortages in the low % ID/g of tumors and high accumulation in the kidney.

Citing Articles

Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.

Wu Y, Shang J, Zhang X, Li N J Nanobiotechnology. 2024; 22(1):783.

PMID: 39702277 PMC: 11657939. DOI: 10.1186/s12951-024-02940-4.


Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.

Zhou Y, Wei R, Wang L, Li J, Wang W, Jiang G J Nanobiotechnology. 2024; 22(1):483.

PMID: 39138475 PMC: 11320875. DOI: 10.1186/s12951-024-02744-6.


Ga-labeled TMTP1 radiotracer for PET imaging of cervical cancer.

Chen X, Sun Y, Li F, Xi L, Dai J, Zhao C Am J Nucl Med Mol Imaging. 2024; 14(2):110-121.

PMID: 38737640 PMC: 11087289. DOI: 10.62347/NFDH6303.


Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.

Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S Signal Transduct Target Ther. 2023; 8(1):367.

PMID: 37752146 PMC: 10522642. DOI: 10.1038/s41392-023-01576-4.


A TMVP1-modified near-infrared nanoprobe: molecular imaging for tumor metastasis in sentinel lymph node and targeted enhanced photothermal therapy.

Wang X, Dai G, Jiang G, Zhang D, Wang L, Zhang W J Nanobiotechnology. 2023; 21(1):130.

PMID: 37069646 PMC: 10108508. DOI: 10.1186/s12951-023-01883-6.